Prevalence of Complementary and Alternative Medicine (CAM) among Diabetic Patients in Eastern Mediterranean Country Members of the World Health Organization (WHO): A Review

2021 ◽  
pp. 100476
Author(s):  
Mohsen Adib-Hajbaghery ◽  
Mojtaba Fattahi Ardakani ◽  
Ahmad Sotoudeh ◽  
Ali Asadian
2018 ◽  
Vol 44 (9) ◽  
pp. 1588-1590 ◽  
Author(s):  
Lama H. Nazer ◽  
Mohamad Elaibaid ◽  
Nada Al-Qadheeb ◽  
Ruth Kleinpell ◽  
Keith M. Olsen ◽  
...  

Vaccine ◽  
2016 ◽  
Vol 34 (21) ◽  
pp. 2403-2409 ◽  
Author(s):  
Robert D. Allison ◽  
Nadia Teleb ◽  
Salah Al Awaidy ◽  
Hossam Ashmony ◽  
James P. Alexander ◽  
...  

2020 ◽  
Vol 23 (10) ◽  
pp. 707-711
Author(s):  
Leila Mounesan ◽  
Ehsan Mostafavi

The honorable Abdul Hussein Tabatabaei was born in 1911 in Iran and received his medical education in the United Kingdom. Famously known as Dr. A.H. Taba, he was a well-respected man for his significant impact on the improvement of the national and global healthcare services and support for social justice. Before joining the World Health Organization (WHO), he was twice elected to the Iranian national assembly and served as the under-secretary of health services in Iran. Later, he joined the WHO and was elected as the Director of the Eastern Mediterranean Region (EMRO) in Alexandria in 1957 – a position he maintained for 25 years. During his tenure as the Regional Director, he rendered valuable assistance to the development and expansion of major health issues such as development and expansion of the health workforce, improvement of the national health services and controlling of various communicable diseases in the member countries and across the WHO regional offices.


2018 ◽  
Vol 6 (3) ◽  
pp. 237-244 ◽  
Author(s):  
Günter Eisele ◽  
Ulrich Roelcke ◽  
Katrin Conen ◽  
Fabienne Huber ◽  
Tobias Weiss ◽  
...  

Abstract Background During the course of disease, most glioma patients learn that there is no cure for their tumor. It is therefore not uncommon for patients or caregivers to seek complementary and alternative medicine (CAM) treatments. Patterns of CAM use vary across the globe, but little is known about the type of, and motivation for, CAM use in most countries. Methods Here we conducted a cross-sectional survey of CAM use in patients harboring gliomas of World Health Organization (WHO) grades II to IV at 3 specialized neuro-oncology centers in Switzerland. Results Of 208 patients who returned the survey, approximately half reported having used or using CAM. CAM use was associated with younger age. Patients suffering from WHO grade II gliomas were less likely to indicate CAM use. The leading motivation for CAM use was to contribute actively to the treatment of the disease. CAM use was commonly not counseled or supervised by a health care professional. Cost and issues of reimbursement were not an important factor in the decision against or for CAM use. Conclusions Physicians caring for glioma patients should be aware of and explore CAM use to better understand patients’ attitudes toward their disease, to provide counseling, and to identify potential interactions of CAM with standard treatments for gliomas.


Sign in / Sign up

Export Citation Format

Share Document